India → US · $80B+/year
US-India trade is one of the fastest-growing bilateral trade relationships in the world — expanding 15%+ annually with no signs of slowing. India is the world's #1 generic pharmaceutical supplier to the US, a growing electronics manufacturer (Apple iPhone production), and a top supplier of diamonds, engineering goods, and textiles. For brokers positioning on high-growth lanes, US-India is the most important emerging corridor.
| Category | Share |
|---|---|
| Pharmaceuticals & APIs | ~24% |
| Diamonds, Gems & Jewelry | ~14% |
| Engineering Goods | ~12% |
| Textiles & Apparel | ~10% |
| Chemicals & Dyes | ~8% |
Sun Pharma, Dr. Reddy's, Cipla US, and dozens of generic drug manufacturers import APIs and finished generics from Indian plants. India supplies 40%+ of all US generic drugs — a massive, growing, regulated freight category requiring specialized documentation and handling expertise.
Surat, India processes 90%+ of the world's traded diamonds. Tiffany, Signet, and hundreds of diamond importers receive Indian shipments regularly. These are extremely high-value, small-weight shipments with security and chain-of-custody requirements.
Apple started iPhone production in India in 2023. Samsung and others have expanded Indian electronics manufacturing. US electronics importers from India are growing rapidly — these are establishing new freight relationships from scratch, making them high-value broker prospects.
Indian textile and apparel imports follow Northern Hemisphere seasonal patterns — Q3 peak for fall/winter goods. Pharmaceutical imports are aseasonal. Diamond imports track jewelry retail cycles — Q4 Christmas peak, Q1 Valentine's Day pulse, Q2 wedding season. Agricultural and spice imports (pepper, cardamom) follow Indian harvest calendars.
| Shipper | Product | US Consignee | Port | Weight |
|---|---|---|---|---|
| SUN PHARMACEUTICAL INDIA | GENERIC PHARMACEUTICAL TABLETS | SUN PHARMA USA INC | New York | 4,800 KG |
| KIRAN GEMS PVT LTD SURAT | CUT AND POLISHED DIAMONDS | SIGNET JEWELERS USA | New York | 24 KG |
| WELSPUN INDIA LTD | COTTON TERRY TOWELS | TARGET CORPORATION | Savannah | 42,000 KG |
| BHARAT FORGE LIMITED | FORGED AUTOMOTIVE PARTS | US AUTO COMPONENTS LLC | Baltimore | 28,400 KG |
"pharmaceutical" or "generic drug" imports from Mumbai or Hyderabad"diamond" or "gemstone" imports from Surat exporters"cotton textile" or "apparel" from Indian textile millsNew India electronics importers — Apple supply chain components"engineering goods" or "auto components" from Indian manufacturersWith 15%+ annual growth driven by China+1 electronics manufacturing, pharmaceutical expansion, and engineering goods, the US-India lane is creating more new freight relationships per year than any other corridor. Apple's India production alone is generating new logistics requirements that existing brokers aren't positioned to serve.
FDA-regulated pharmaceutical imports require precise documentation, temperature chain management, and FDA clearance expertise. Brokers who master pharmaceutical freight compliance on the India-US lane build some of the most valuable accounts in the industry — high retention, premium rates, and strong barriers to competition.
Trans-Pacific and Europe lanes are well-served by established brokers. India-specific expertise — understanding Indian port dynamics, customs requirements, and the specific product categories — is relatively rare. Early specialization creates disproportionate advantage as the lane grows.
New York/New Jersey handles the largest share of Indian imports — pharmaceutical, diamonds, textiles, and engineering goods. Los Angeles/Long Beach is growing rapidly for Indian electronics. Savannah handles significant Indian textile volume destined for Southeast US distribution. Baltimore receives engineering goods and auto parts.
Dramatically. Apple shifted significant iPhone production to India starting 2023, and Samsung and others have expanded Indian factories. Electronics now represent approximately 15% of Indian exports to the US and are growing 30%+ annually — the fastest-growing major India export category.
Yes. Generic pharmaceutical imports require FDA documentation, controlled storage in some cases, chain-of-custody records, and customs clearance expertise specific to pharmaceutical imports. GxP compliance expertise is required for many active pharmaceutical ingredient imports. These requirements create expertise-based barriers that protect specialist brokers.
US-China has vastly more total volume but is a competitive lane with established broker relationships. US-India has less volume but 15%+ annual growth, less broker competition, and higher specialization value. A broker positioning on US-India now is in a different competitive position than one entering US-China today.
10M+ records. Filter by lane, product, port, or company.
Get Early Access — $49/mo →Also: All trade lanes · By origin country · By port